FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1805 November 28, 2002 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Haberer, J. E. PubMed Citation

To the Editor: The patient with systemic lupus erythematosus and tuberculosis described in the Clinical Problem-Solving article by Haberer et al. (May 2 issue)¹ could have been identified as being at high risk for reactivation of tuberculosis before the initiation of immunosuppressive therapy. Isoniazid prophylaxis has been reported to be effective and safe in patients with systemic lupus erythematosus and might have been considered when the immunosuppressive therapy was started.^2,3 This case underscores the importance of assessing the risk of infectious complications in immunocompromised patients.

Rainald A. Zeuner, M.D.
University of Kiel
24116 Kiel, Germany

1. Haberer JE, Ix JH, Tierney LM Jr. One foot away. N Engl J Med 2002;346:1394-1397. [Free Full Text]
2. Gilliland WR, Tsokos GC. Prophylactic use of antibiotics and immunisations in patients with SLE. Ann Rheum Dis 2002;61:191-192. [Free Full Text]
3. Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002;61:251-253. [Free Full Text]